α2-antiplasmin on cardiovascular diseases

Current Pharmaceutical Design

Volumn 12, Issue 7, 2006, Pages 841-847

  Matsuno, Hiroyuki ^a  

^a DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

Plasminogen activator inhibitors (PAIs); Thrombolytic; Vascular diseases; Vascular endothelial growth factor (VEGF); VENOUS THROMBOSIS

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR; VASCULOTROPIN; ANTIPLASMIN; VASCULOTROPIN A;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD VESSEL INJURY; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CELL INVASION; CHRONIC DISEASE; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEART FAILURE; HEMOSTASIS; HUMAN; IN VIVO STUDY; INFLAMMATORY DISEASE; KIDNEY DISEASE; LUNG DISEASE; LUNG EDEMA; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; THROMBOGENESIS; VEIN THROMBOSIS; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPLASMIN; CARDIOVASCULAR DISEASES; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645285335     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776056038     Document Type: Review

References (73)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78:3114-24.
2. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8(2): 277-90.
3. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-9.
4. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1:light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299.
5. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312.
6. Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arteriosc Thromb 1994; 14, 1452-1458.
7. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
8. Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33.
9. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993; 72: 413-21.
10. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Cullen D. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81: 601-604.
11. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor- 1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-5.
12. Koie K, Kamiya T, Ogata K, Takamatsu J. Alpha2-plasmin-inhibitor deficiency (Miyasato disease). Lancet 1978; 2(8104-5): 1334-6.
13. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63(5): 877-84.
14. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
15. Vassalli JD, Sappino AP, Belin D.The plasminogen activator/plasmin system. J Clin Invest 1991; 88(4): 1067-72.
16. Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236(4): 425-32.
17. Fuster V, Badimon L, Badimon JJ, Chesebro JH.The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326(4): 242-50.
18. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods 1991; 25: 303-317.
19. Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br J Pharmacol 1992; 106: 533-538.
20. Matsuno H, Uematsu T, Nakashima M. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. Br J Pharmacol 1993; 110: 1278-1279.
21. Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura. K, Uematsu T, et al. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 1993; 231: 421-425.
22. Matsuno H, Uematsu T, Kozawa O, Niwa M, Ueshima S, Matsuo O. Fibrinolytic factors play a different role on the development or lysis of thrombus formation. Thromb Haemost 1999; 81: 601-604.
23. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thromb Haemost 2002; 87(1): 98-104.
24. Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Buller HR. Travel and risk of venous thrombosis. Lancet 2000; 356: 1492-3.
25. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997; 39: 343-50.
26. Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood 1982; 59: 1169-80.
27. Aoki N, Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 99-105.
28. Teger-Nilsson AC, Gyzander E, Myrwold H, Noppa H, Olsson R, Wallmo L. Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. Haemostasis 1978; 7: 155-7.
29. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43-8.
30. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93: 2274-81.
31. Fuentes A, Rojas A, Porter KB, Saviello G, O'Brien WF. The effect of magnesium sulfate on bleeding time in pregnancy. Am J Obstet Gynecol 1995; 173: 1246-9.
32. Matsuno H, Kozawa O, Niwa M, Tanabe K, Ichimaru K, Takiguchi Y, et al. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost 1998; 79: 865-71.
33. Ito T, Matsuno H, Kozawa O, Niwa M, Sakai N, Uematsu T. Comparison of the antithrombotic effects and bleeding risk of fractionated ATA and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis. Thromb Res 1999; 95: 49-61.
34. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis sis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
35. Sutton GC, Hall RJ, Keff IH. Clinical course and late prognosis of treated subacute massive, acute minor, and chronic pulmonary thromboembolism. Br Heart J 1997; 10: 1135-42.
36. Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000; 102: 1151-7.
37. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost 2001; 86: 444-51.
38. Okada K, Lijnen HR, Dewerchin M, Belayew A, Matsuo O, Collen D, et al. Characterization and targeting of the murine alpha2-antiplasmin gene. Thromb Haemost 1997; 78: 1104-10.
39. Menoud PA, Sappino N, Boudal-Khoshbeen M, Vassalli JD, Sappino AP. The kidney is a major site of alpha(2)-antiplasmin production. J Clin Invest 1996; 97: 2478-84.
40. Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasniin-deficient mice. Blood Coagul Fibrinolysis 2000; 11(7): 645-55.
41. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 2001; 86(2): 640-6.
42. Lee KN, Tae WC, Jackson KW, Kwon SH, McKee PA. Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant. Blood 1999; 94: 164-71.
43. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-3806.
44. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264: 20017-20024.
45. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257(5075): 1401-1403.
46. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med 1995; 10: 1085-1089.
47. Brown LF, Yen KT, Berse B, Yeo TK, Senger DR, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375-1379.
48. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 21994; 8: 1176-1179.
49. Seko Y, Imai Y, Suzuki S, Kamijukkoku S, Hayasaki K, Sakomura Y, et al. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci (Lond) 1997; 92: 453-454.
50. Hojo Y. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000; 35: 968-973 (2000).
51. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
52. Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997; 62: 397-400
53. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothclial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
54. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-26037.
55. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrixbound VEGF. Mol Biol Cell 1993; 4:1317-1326.
56. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, et al. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002; 100(7): 2487-93.
57. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998; 95: 15809-15814.
58. Tuder RM, Flock BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798-1807.
59. Pancholi V, Fischetti VA. Alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 1998; 273: 14503-15
60. Kim J, Hajjar KA. Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 2002; 7: D341-8.
61. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000; 22: 657-664.
62. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-3806.
63. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002; 4: E2-5.
64. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
65. Taghavi S, Abraham D, Riml P, Paulus P, Schafer R, Klepetko W, et al. Co-expression of endothelin-1 and vascular endothelial growth factor mediates increased vascular permeability in lung grafts before reperfusion. J Heart Lung Transplant 2002; 21: 600-603.
66. Matsuno H, Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, et al. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002; 100: 2487-2493.
67. Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 2002; 132: 93-98.
68. Spyridopoulos I, Luedemann C, Chen D, Kearney M, Chen D, Murohara T, et al. Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arterioscler Thromb Vasc Biol 2002; 22: 901-906.
69. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, et al. Related Articles, Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 1997; 811: 191-206.
70. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, et al. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81: 601-604.
71. Gruchala M, Roy H, Bhardwaj S, Yla-Herttuala S. Gene therapy for cardiovascular diseases. Curr Pharm Des 2004; 10(4): 407-23.
72. Tomita N, Morishita R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Des 2004; 10(7): 797-803.
73. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10(27): 3331-48.